Dacomitinib (PF299804, PF299)
≥99.8%
- Product Code: 55193
CAS:
1110813-31-4
| Molecular Weight: | 469.94 g./mol | Molecular Formula: | C₂₄H₂₅ClFN₅O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, dry, sealed |
Product Description:
Dacomitinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer has specific mutations in the epidermal growth factor receptor (EGFR). It functions as an irreversible inhibitor of the EGFR tyrosine kinase, which helps in blocking the signaling pathways that promote cancer cell growth and survival. This makes it effective in slowing down the progression of the disease in patients with EGFR-mutated NSCLC. It is often prescribed when other treatments, such as first-generation EGFR inhibitors, have failed or are no longer effective. Additionally, dacomitinib may be used in combination with other therapies to enhance its efficacy in managing advanced stages of lung cancer.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Light yellow powder to crystal |
| PURITY | 99.8-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | ฿16,600.00 |
+
-
|
| 0.250 | 10-20 days | ฿24,200.00 |
+
-
|
| 1.000 | 10-20 days | ฿62,400.00 |
+
-
|
Dacomitinib (PF299804, PF299)
Dacomitinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer has specific mutations in the epidermal growth factor receptor (EGFR). It functions as an irreversible inhibitor of the EGFR tyrosine kinase, which helps in blocking the signaling pathways that promote cancer cell growth and survival. This makes it effective in slowing down the progression of the disease in patients with EGFR-mutated NSCLC. It is often prescribed when other treatments, such as first-generation EGFR inhibitors, have failed or are no longer effective. Additionally, dacomitinib may be used in combination with other therapies to enhance its efficacy in managing advanced stages of lung cancer.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :